Clinical trials: BCC
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
This phase II MATCH treatment trial tests how well GDC-0449 (vismodegib) works for treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma
- Trial name
- NCT06357988
- Testing
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Carcinoma, Gorlin Syndrome
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
This was a phase II, double-blind, randomized, proof-of-concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with NBCCS.
- Conditions
- Basal Cell Carcinoma, Gorlin Syndrome, Nevoid Basal Cell Carcinoma Syndrome
- Trial name
- NCT01350115
- Testing
- LDE225
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Nodular Basal Cell Carcinoma, Superficial Basal Cell Carcinoma
Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
Laser therapy for basal cell carcinoma may be a superior option for patients who do not wish to or cannot tolerate other treatment modalities such as topical chemotherapeutics or surgery.
- Trial name
- BCC (NCT02270645)
- Testing
- 595/1064 multiplex laser
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Miami
Basal Cell Carcinoma
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells.
- Trial name
- NCT00472043
- Testing
- PDT with Metvix 160 mg/g cream
- Where
- 7 sites in Australia
- Volunteers
- 66 people
- Sponsor
- Galderma R&D
Superficial Basal Cell Carcinoma
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.
- Trial name
- NCT00189306
- Testing
- Imiquimod 5% cream
- Where
- 18 sites in Australia, New Zealand
- Volunteers
- 169 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Melanoma, Basal Cell Carcinoma
The Impact of Total Body Skin Examination on Skin Cancer Detection
This will be a study where all patients will undergo a two-step procedure: Step 1 - Physicians examine the problem area of skin ONLY and record result. Step 2 - Physicians perform TBSE and record result.
- Conditions
- Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- TBSE (NCT00765193)
- Testing
- Inspection of covered areas
- Where
- Austria
- Volunteers
- 14,381 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ
Pilot Study of PDL to Treat BCC and SCCIS
This is a research study to find out more about the use of the pulsed dye laser in the treatment of basal cell carcinoma and early stage squamous cell carcinoma that has not invaded deep into the skin.
- Trial name
- PDLNMSC (NCT01245972)
- Testing
- PDL Treatment
- Volunteers
- 23 people
- Sponsor
- University of California, San Diego
BCC - Basal Cell Carcinoma, BCC
CellFX Treat & Resect Low-Risk BCC Feasibility Study
This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of…
- Conditions
- BCC - Basal Cell Carcinoma, BCC, Excision Margin
- Trial name
- NCT04918381
- Testing
- CellFX System
- Where
- 5 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pulse Biosciences, Inc.
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.
- Trial name
- NCT01631331
- Testing
- vismodegib, Mohs surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stanford University
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer.
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT04916002
- Testing
- vidutolimod, cemiplimab
- Where
- 24 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Basal Cell (BCC)
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
This is a Phase 1, open-label, single-arm, multicenter study to assess the safety and tolerability of BSCT (anti-nf-P2X7) 10% Ointment in subjects with BCC.
- Trial name
- NCT02587819
- Testing
- Treatment with BSCT
- Volunteers
- 21 people
- Sponsor
- Biosceptre
Skin Cancer, Skin Cancer Melanoma
Strategies to Promote Skin Health
The purpose of the intended proposed research is to investigate and determine best strategies for preventing skin cancer for emerging adults.
- Conditions
- Skin Cancer, Skin Cancer Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma
- Trial name
- NCT03237013
- Testing
- Facial Morphing Intervention, Mindfulness Intervention
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- San Diego State University
Skin Basal Cell Carcinoma
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery.
- Trial name
- NCT02690948
- Testing
- Pembrolizumab, Vismodegib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Anne Chang
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing…
- Trial name
- ATO (NCT01791894)
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Carcinoma, Basal Cell, Recurrent Skin Cancer
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body.
- Conditions
- Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
- Trial name
- NCT02303041
- Testing
- Buparlisib, Sonidegib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Anne Chang
Basal Cell Carcinoma
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
This randomized, double-blind, regimen-controlled, phase II, multicenter study will assess the efficacy and safety of two different vismodegib regimens in participants with multiple basal cell carcinoma.
- Trial name
- NCT01815840
- Testing
- Vismodegib
- Where
- 58 sites in United States, Austria and 8 more
- Volunteers
- 229 people
- Sponsor
- Hoffmann-La Roche
Basal Cell Carcinoma
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
This is a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma.
- Trial name
- NCT00833417
- Testing
- Vismodegib 150 mg
- Where
- 36 sites in United States, Australia and 4 more
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Nodular Basal Cell Carcinoma
Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.
- Trial name
- NCT01808950
- Testing
- 0.06% Resiquimod Gel - A, 0.06% Resiquimod Gel - B, 0.06% Resiquimod Gel - C
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 4 people
- Sponsor
- Spirig Pharma Ltd.
Basal Cell Carcinoma
Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma
The purpose of this study is to evaluate the efficacy of pdt in treatment of bcc and factors that affect response rate.
- Trial name
- NCT00985829
- Testing
- photodynamic therapy
- Volunteers
- 28 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Solid Cancers
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
- Trial name
- NCT00968981
- Testing
- GDC-0449
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.